JPMorgan ETFs (Ireland) ICAV - Europe Research Enhanced Index Equity UCITS ETF - EUR (acc) | JREERegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 3.7 | 17.8 | -4.3 | 14.4 | 4.8 | |
+/-Cat | -0.6 | 2.5 | 4.0 | 2.9 | 1.0 | |
+/-B’mrk | 1.2 | 0.2 | 0.3 | 1.3 | -0.7 | |
Category: Europe Large-Cap Blend Equity | ||||||
Category Benchmark: Morningstar DM Eur TME NR EUR |
Key Stats | ||
Closing Price 20/11/2024 | EUR 41.45 | |
Day Change | -0.57% | |
Morningstar Category™ | Europe Large-Cap Blend Equity | |
Volume | 414 | |
Exchange | LONDON STOCK EXCHANGE, THE | |
ISIN | IE00BF4G7183 | |
Fund Size (Mil) 20/11/2024 | EUR 1806.32 | |
Share Class Size (Mil) 20/11/2024 | EUR 1756.46 | |
Ongoing Charge 19/07/2024 | 0.25% |
Investment Objective: JPMorgan ETFs (Ireland) ICAV - Europe Research Enhanced Index Equity UCITS ETF - EUR (acc) | JREE |
The objective of the Sub-Fund is to achieve a long-term return in excess of the Benchmark by actively investing primarily in a portfolio of European companies. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Piera Grassi 14/05/2019 | ||
Nicholas Farserotu 30/06/2020 | ||
Inception Date 10/10/2018 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe NR EUR | Morningstar DM Eur TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for JPMorgan ETFs (Ireland) ICAV - Europe Research Enhanced Index Equity UCITS ETF - EUR (acc) | JREE | 31/08/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk A/S Class B | Healthcare | 4.45 |
ASML Holding NV | Technology | 3.79 |
Nestle SA | Consumer Defensive | 3.27 |
AstraZeneca PLC | Healthcare | 3.14 |
Shell PLC | Energy | 2.72 |
Increase Decrease New since last portfolio | ||
JPMorgan ETFs (Ireland) ICAV - Europe Research Enhanced Index Equity UCITS ETF - EUR (acc) | JREE |